ZYDUS LIFESCIENCES LTD (532321) — Latest Corporate Announcements
₹1,127.2
₹-7.20 (-0.63%)
Market Cap
₹1,12,438.62 Cr
P/E Ratio
25.12
52W Range
₹835.5 – ₹1232.1
Corporate Actions & Regulatory Filings
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA".
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 12, 2026, titled "Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC".
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Updates on Joint Venture
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Credit Rating
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Newspaper Publication
Settlement Agreement
Transcript Of The 31St Annual General Meeting
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Incorporation Of A Wholly Owned Subsidiary In Gift City, Gandhinagar, Gujarat
ESG Rating
Financial Results (Quarterly & Annual)
| Quarter / Period | Meeting / Outcome Date | Status | Filing Details |
|---|---|---|---|
| Quarter Ended 30-Jun-2026 (Q1 FY27) | 11 Aug 2026 | Declared |
Unaudited Financial Results For The Quarter Ended On June 30, 2026
📄 View Quarter Ended 30-Jun-2026 (Q1 FY27) Results PDF ↗ |
| Year Ended 31-Mar-2026 (Q4 FY26) | 19-May-2026 | Declared | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| Quarter Ended 31-Dec-2025 (Q3 FY26) | 09-Feb-2026 | Declared | To consider and approve the financial results for the period ended December 31, 2025 |
| Quarter Ended 30-Sep-2025 (Q2 FY26) | 06-Nov-2025 | Declared | To consider and approve the financial results for the period ended September 30, 2025 |
| Quarter Ended 30-Jun-2025 (Q1 FY26) | 12-Aug-2025 | Declared | To consider and approve the financial results for the period ended Jun 30, 2025 |
| Year Ended 31-Mar-2025 (Q4 FY25) | 20-May-2025 | Declared | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
| Quarter Ended 31-Dec-2024 (Q3 FY25) | 05-Feb-2025 | Declared | To consider and approve the financial results for the period ended December 31, 2024 |
| Quarter Ended 30-Sep-2024 (Q2 FY25) | 12-Nov-2024 | Declared | To consider and approve the financial results for the period ended September 30, 2024 |
| Quarter Ended 30-Jun-2024 (Q1 FY25) | 09-Aug-2024 | Declared | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Year Ended 31-Mar-2024 (Q4 FY24) | 17-May-2024 | Declared | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Quarter Ended 31-Dec-2023 (Q3 FY24) | 09-Feb-2024 | Declared | To consider and approve the financial results for the period ended December 31, 2023 |
| Quarter Ended 30-Sep-2023 (Q2 FY24) | 07-Nov-2023 | Declared | To consider and approve the financial results for the period ended September 30, 2023 |
Track Related Peer Equities
Related Research Guides & Regulatory Playbooks
Frequently Asked Questions about ZYDUS LIFESCIENCES LTD BSE Disclosures
What is the latest BSE announcement by ZYDUS LIFESCIENCES LTD?
The latest BSE disclosure by ZYDUS LIFESCIENCES LTD (ZYDUSLIFE), filed on 2026-10-13T09:50:10, is: "Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release". Bsenexus tracks every official filing for ZYDUS LIFESCIENCES LTD with AI-powered summaries on its announcements feed.
When is ZYDUS LIFESCIENCES LTD's next board meeting?
No upcoming board meeting is currently tracked for ZYDUS LIFESCIENCES LTD. Companies disclose meeting intimations under SEBI LODR, and scheduled dates appear on the Bsenexus Results Calendar.
When does ZYDUS LIFESCIENCES LTD declare quarterly results?
Under SEBI (LODR) Regulation 33, listed companies submit quarterly unaudited results within 45 days of the quarter ending, and annual audited figures within 60 days. ZYDUS LIFESCIENCES LTD's recent results history is tabulated above. Track scheduled board meetings on the Bsenexus Results Calendar.